A new grant aims to address maternal mortality in predominantly Black rural areas; Eli Lilly's drug to treat atopic dermatitis has not received FDA approval; a preliminary injunction is granted to Planned Parenthood South Atlantic.
A federal program under the Health Resources and Services Administration has awarded its first grant to an organization serving predominantly Black rural communities in the Deep South to combat high maternal mortality rates, according to Kaiser Health News. This development follows concerns raised after the Rural Maternity and Obstetrics Management Strategies Program initially omitted grants for such communities, despite their alarming maternal mortality rates. The Mississippi-based Institute for the Advancement of Minority Health and Mary Hitchcock Memorial Hospital in New Hampshire are among the latest grant recipients. These efforts aim to reduce maternal health disparities in areas with historically high rates of maternal mortality, especially among Black women.
The FDA has declined to approve Eli Lilly's drug lebrikizumab, intended for treating atopic dermatitis, according to Reuters. This decision results from certain findings during an inspection of a contract manufacturer, with the FDA not raising concerns about clinical trial data, safety, or labeling. Lilly plans to collaborate with the manufacturer and the FDA to address the issues cited in the complete response letter. Analysts estimate that lebrikizumab could generate $1.64 billion in sales by 2026.
District Judge Catherine Eagles has lifted some restrictions in North Carolina's abortion ban, granting a preliminary injunction to Planned Parenthood South Atlantic, according to The Hill. This ruling affects portions of the ban that required documentation of intrauterine pregnancy and mandated surgical abortions to be performed in a hospital after 12 weeks. Eagles had previously blocked the pregnancy documentation requirement in June, when the 12-week ban was signed into law. The decision was praised by Planned Parenthood and North Carolina Attorney General Josh Stein, who called the law “sloppily written.” This development comes in the context of increased abortion restrictions in several US states following the Supreme Court’s decision to overturn Roe v Wade.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More